CNSystems to present CNAP blood circulation pressure measuring device data in International Symposium This is a great success for CNSystems. The well-established Austrian hi-tech company will become presenting its CNAP blood pressure measuring device, as well as, for the first time, evaluation data at the International Symposium on Intensive Care and Emergency Medication in Brussels review . In the last years, CNSystems primarily demonstrated its competence in the field of blood pressure measurement in anaesthesia and cardiology. With the CNAP-Monitor the high-tech business succeeded in creating a gadget for the constant blood circulation pressure measurement of every single heartbeat without puncturing your body with a needle. ‘Up to now during procedures the doctor either had to place an arterial catheter or fall back on top arm measurement, which only provides a value every 3 to a quarter-hour,’ explains the head of CNSystems, Juergen Fortin. ‘Our device methods the blood circulation pressure painlessly, non-invasively and at exactly the same time continuously instantly, thus detecting life-threatening changes immediately. This could save lives.’ Related StoriesVISERA 4K UHD endoscopy program gives surgeons 4x resolutionBetter visualization in complex reconstructive medical procedures with ZEISS Opmi Pentero 800 surgical microscopeAmputation isn’t wound healingThis kind of blood circulation pressure measurement is allowed by a dual finger cuff, which records a accurate blood circulation pressure curve highly. The cuff, the software and the mechanism are protected worldwide by a lot more than 50 patents. The reliability and accuracy of the CNAP measurement during functions have been confirmed in scientific trials by renowned universities. However, not only the CNAP gadget will be demonstrated at the Symposium in Brussels, but also evaluation data from intensive treatment will be scientifically offered for the first time. ‘We use the device on significantly ill patients at its highest functionality level. This way we gain useful data that help to monitor these individuals optimally and ultimately, above all, painlessly,’ explains the main researcher, Univ.-Doz. Karl-Heinz Smolle from Graz University Hospital. ‘And this is what matters ultimately.’ CNSystems is an Austrian, privately-possessed, medical technology organization and technological head in noninvasive, continuous blood pressure measurement.
COX-2 expression no adequate independent prognostic factor: Research Cyclooxygenase-2 represents a key modulatory molecule in swelling and carcinogenesis. COX-2 may have multiple tumorigenic effects. Elevated expression of COX-2 has been observed in a variety of tumors including pancreatic cancer. In the literature, the prognostic significance of COX-2 expression like the function of antibody utilized for an assessment of COX-2 expression profile have already been discussed. A substantial inverse relationship between COX-2 overexpression and survival prices offers previously been reported in retrospective research of different types of malignancies. Conflicting outcomes have been proven in pancreatic cancers and the possible role of primary antibody used for the detection of COX-2 expression offers been suggested. Related StoriesViralytics enters into medical trial collaboration contract with MSDNew RNA test of blood platelets can be used to detect area of cancerScientists discover small molecule that may block growth of BRCA-deficient malignancy cellsA research content to be published on April 21, 2010 in the global world Journal of Gastroenterology addresses this question. The overexpression of COX-2 was demonstrated in a significant proportion of pancreatic ductal adenocarcinomas using both monoclonal and polyclonal antibodies and a romantic relationship of COX-2 to the biological process of pancreatic cancer was verified. Using the monoclonal antibody, a significantly shorter disease free survival was found in patients with COX-2 positive tumors. No significant results were obtained in regards to to overall survival. High histological grade and nodal involvement were associated with shorter survival significantly. In conclusion, the known degree of COX-2 expression will not seem to be a very important independent prognostic factor. Immunohistochemical evaluation of COX-2 expression is not superior to the traditional prognostic elements such as grade, nodal and stage status.